Galen Prostate by IBEX achieved an AUC of 0.941 for distinguishing between low-grade and high-grade cancer. 50 DeepDX Prostate by Deep Bio achieved a high diagnostic concordance to the reference stand ...

Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...

Prostate cancer remains the most commonly diagnosed cancer in men in the United States, with nearly 300,000 new cases expected by the end of 2024. According to the American Cancer Association, ...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer The new, tissue-based test service is intended to ...

The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive surgical margins occur in 15–40% of prostate cancer cases, the risk of ...

Grade group 1 prostate cancer assessment should include PSA, stage, and disease volume for accurate risk evaluation. Active surveillance is safe for most low-risk patients, but higher-risk features ...

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Researchers have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive ...

In a study believed to be the first of its kind published, a research team led by Johns Hopkins Medicine provides scientific evidence that a healthy diet may reduce the chance of low risk prostate ...